NWAM LLC’s Adverum Biotechnologies ADVM Stock Holding History

NWAM LLC’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,000	Closed	-$7.53K	–	558
2023 Q4	$7.53K	Hold	1,000	–	–	﹤0.01%	552
2023 Q3	$15K	Hold	1,000	–	–	﹤0.01%	499
2023 Q2	$15.9K	Hold	1,000	–	–	﹤0.01%	532
2023 Q1	$7.17K	Hold	1,000	–	–	﹤0.01%	479
2022 Q4	$5.79K	Hold	1,000	–	–	﹤0.01%	511
2022 Q3	$10K	Hold	1,000	–	–	﹤0.01%	481
2022 Q2	$12K	Hold	1,000	–	–	﹤0.01%	512
2022 Q1	$13K	Hold	1,000	–	–	﹤0.01%	521
2021 Q4	$18K	Hold	1,000	–	–	﹤0.01%	504
2021 Q3	$22K	Hold	1,000	–	–	﹤0.01%	492
2021 Q2	$35K	Hold	1,000	–	–	﹤0.01%	467
2021 Q1	$99K	Hold	1,000	–	–	0.01%	479
2020 Q4	$108K	Hold	1,000	–	–	0.01%	444
2020 Q3	$103K	Hold	1,000	–	–	0.02%	235
2020 Q2	$209K	Buy	+1,000	New	+$177K	0.03%	373

Other funds holding ADVM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

NWAM LLC's ADVM Position: Q1 2024 in Review

NWAM LLC sold out of Adverum Biotechnologies (ADVM) in Q1 2024, closing a stake of 1,000 shares — an estimated $7.53K sold.

NWAM LLC first reported a position in ADVM in Q2 2020 and held it in 15 quarters. The position peaked at $209K in Q2 2020. 61 funds tracked by Wall St. Rank hold ADVM as of Q1 2024.

NWAM LLC reported no remaining Adverum Biotechnologies position as of Q1 2024 after selling out during the quarter.
NWAM LLC sold 1,000 Adverum Biotechnologies shares in Q1 2024, an estimated $7.53K.
NWAM LLC first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 15 quarters.
NWAM LLC's Adverum Biotechnologies position peaked at $209K in Q2 2020.
61 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2024.

Based on NWAM LLC's 13F filing for Q1 2024, filed 9 May 2024.